Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1270 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Forest Labs to buy Clinical Data

The purchase price is $30 per share in cash plus contingent consideration of up to $6 per share that may be paid upon achievement of certain commercial milestones

Gilead to acquire Calistoga Pharma for $375m

Calistoga could earn up to an additional $225m if certain milestones are achieved. Calistoga’s lead product candidate, CAL-101, is a first-in-class specific inhibitor of the PI3K delta isoform.